Nivolumab/Relatlimab Shows Sustained Efficacy in Advanced Melanoma
Source: Cancer Network, February 2025
Data from RELATIVITY-047 show consistent benefits with nivolumab/relatlimab across most patient subgroups, including those with BRAF-mutated disease.
Combining nivolumab (Opdivo) with relatlimab (Opdualag) yielded sustained, statistically significant improvements in progression-free survival (PFS) and other efficacy outcomes vs nivolumab alone in patients with previously untreated metastatic or unresectable advanced melanoma, according to data from the phase 2/3 RELATIVITY-047 study (NCT03470922) published in The Journal of Clinical Oncology.
Nivolumab/relatlimab produced a median PFS of 10.2 months (95% CI, 6.5-15.4) vs 4.6 months (95% CI, 3.5-6.5) in patients who received nivolumab monotherapy (HR, 0.79; 95% CI, 0.66-0.95). The PFS rates at 3 years were 31.8% (95% CI, 26.6%-37.1%) vs 26.9% (95% CI, 22.1%-31.9%) in each respective arm.